ALLMedicine™ Mevalonate Kinase Deficiency Center

Apr 13th, 2022 - Assessment of the medical fitness to serve in the armed forces has two objectives: to prevent the military operations from being jeopardized by a medical issue, and to protect soldiers from the sequelae of diseases that could become complicated in...

Feb 15th, 2022 - We report 7 years of follow-up data on ocular findings in a 2-month-old boy who presented with early-onset bilateral granulomatous panuveitis with subsequent development of secondary glaucoma and total cataract, along with multisystem involvement....

Nov 24th, 2021 - Mevalonate kinase deficiency (MKD) is a rare autoinflammatory condition caused by biallelic loss-of-function (LOF) mutations in mevalonate kinase (MVK) gene encoding the enzyme mevalonate kinase. Patients with MKD display a variety of non-specific...

Oct 9th, 2021 - To evaluate the effect of canakinumab on health-related quality of life (HRQoL), work/school and social life of patients with autoinflammatory recurrent fever syndromes, including colchicine-resistant familial Mediterranean fever, mevalonate kinas...

Sep 24th, 2021 - To evaluate the long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficiency during the open label extension (weeks 41-113) of the randomized controlled CLUSTER trial. During a 72-week period, patients received open-l...

Feb 19th, 2020 - Rare autoinflammatory diseases (AIDs) including Cryopyrin-Associated Periodic Syndrome (CAPS), Tumor Necrosis Receptor-Associated Periodic Syndrome (TRAPS) and Mevalonate Kinase Deficiency Syndrome (MKD)/ Hyper-IgD Syndrome (HIDS) are genetically ...

Jul 2nd, 2020 - Recent understanding of the physiopathological mechanisms that underpin autoinflammatory diseases (AIDs) allowed a revolution in the therapeutic management of these patients, particularly through the use of biotherapies. However new treatments nee...

May 17th, 2018 - This study consists of 3 randomized cohorts (one per condition of colchicine resistant/intolerant Familial Mediterranean Fever (crFMF), Hyper Immunoglobulin D Syndrome (also known as mevalonate kinase deficiency (HIDS/MKD), and Tumor Necrosis Fact...

Jan 31st, 2013 - Background: Genetics is suggested to play a critical role in the development of Behçet's disease (BD). Shared phenotypic features requires an approach to the differential diagnosis from periodic febrile syndromes particularly from mevalonate kinas...

Jun 19th, 2020 - The Food and Drug Administration has expanded the indications for canakinumab (Ilaris) to include all patients with active Still's disease older than 2 years, adding adult-onset Still's disease (AOSD) to a previous approval for juvenile-onset Stil...

Jun 18th, 2020 - The Food and Drug Administration has expanded the indications for canakinumab (Ilaris) to include all patients with active Still’s disease older than 2 years, adding adult-onset Still’s disease (AOSD) to a previous approval for juvenile-onset Stil.

Mar 4th, 2020 - NHS England is funding a 'life-changing treatment' for certain individuals with periodic fever syndromes (PFS), a group of rare conditions characterised by fever, joint pains and swelling. Patients with PFS often experience inflammatory 'flares' i...

May 16th, 2018 - Action Points Note that three randomized trials, in different populations of patients with monogenic autoinflammatory diseases, showed a dramatic response to the (IL)-1β antibody canakinumab compared with placebo. One advantage to the drug is the ...

Sep 26th, 2016 - The US Food and Drug Administration (FDA) has approved three new indications for the interleukin-1-β inhibitor canakinumab (Ilaris, Novartis). They are tumor necrosis factor receptor–associated periodic syndrome (TRAPS), hyperimmunoglobulin D synd...